Table 1

Clinical characteristics and treatment at baseline

Cohort B
(n=662)
Cohort H
(n=629)
P value
Age, mean (SD), years65.6±12.964.6±13.30.15
Body mass index, mean (SD)28.6±21.728.5±17.30.93
Male gender, n (%)473 (71.5%)483 (76.8%)0.03
Medical history, n (%)
  Coronary artery disease152 (23.0%)134 (21.3%)0.47
  Myocardial infarction113 (17.1%)92 (14.6%)0.23
  CABG23 (3.5%)20 (3.2%)0.77
  Coronary revascularisation88 (13.3%)74 (11.8%)0.41
  Stroke/TIA >1 year29 (4.4%)16 (2.5%)0.07
  Peripheral arterial disease31 (4.7%)25 (4.0%)0.21
  Congestive heart failure6 (0.9%)7 (1.1%)0.71
  Hypertension354 (53.5%)303 (48.2%)0.06
  Hypercholesterolaemia307 (46.4%)294 (46.7%)0.90
  Diabetes101 (15.3%)83 (13.2%)0.29
  Current smoker216 (32.6%)248 (39.4%)0.01
Long-term antiplatelet therapy, n (%)
  Aspirin256 (38.7%)243 (38.6%)0.99
EKG presentation, n (%)
  ST elevation640 (96.7%)608 (96.7%)0.99
  LBBB10 (1.5%)7 (1.1%)0.53
EKG territory of infarction, n (%)
  Anterior223 (33.7%)229 (36.4%)0.31
Cardiogenic shock, n (%)82 (12.4%)77 (12.2%)0.94
Ventilated patients, n (%)59 (8.9%)57 (9.1%)0.93
Out-of-hospital cardiac arrest, n (%)69 (10.4%)66 (10.5%)0.97
Anticoagulation, n (%)
  Bivalirudin498 (75.2%)5 (0.8%)<0.01
  Heparin164 (24.8%)624 (99.2%)<0.01
Recent lysis, n (%)1 (0.2%)0 (0%)
Gp2b3a agent, n (%)154 (22.3%)177 (28.1%)0.05
  Tirofiban38 (5.7%)22 (3.5%)0.06
  Abciximab116 (17.5%)155 (24.6%)<0.01
Loading dose of antiplatelet, n (%)633 (95.6%)611 (97.1%)0.15
Antiplatelet therapy received between randomisation and discharge, n (%)
  Aspirin652 (98.5%)617 (98.1%)0.58
Oral P2Y12 blocker, n (%)
  Clopidogrel134 (20.2%)75 (11.9%)<0.01
  Prasugrel411 (62.1%)362 (57.6%)0.10
  Ticagrelor117 (17.7%)192 (30.5%)<0.01
  • CABG, coronary artery bypass graft; Gp2b3a, glycoprotein 2b3a; LBBB, left bundle branch block.; TIA, transient ischaemic attack.